AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20919993 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning in rats (three cycles of 10-s reperfusion and 10-s coronary re-occlusion)
Number of subjects: 0
Study 20919993 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective iNOS inhibitor 1400W
Number of subjects: 0
Study 20919993 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-morpholinosydnonimine (ONOO- donor)
Number of subjects: 0
Study 20919993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postconditioning)
Number of subjects: 0
Study 19698147 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupoints of the stomach meridian
Number of subjects: 120
Study 19698147 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific acupoints of the stomach meridian
Number of subjects: 120
Study 19698147 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupoints of alarm and transport points
Number of subjects: 120
Study 19698147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoints of the gallbladder meridian
Number of subjects: 120
Study 19698147 — intervention group
Group type: COMPARATOR
Intervention: Drug (positive control) group
Number of subjects: 120
Study 19698147 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint control group
Number of subjects: 120
Study 16424063 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTCs) - 600 mg/d (three capsules of 200 mg each)
Number of subjects: 60
Study 16424063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16424063 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTCs)
Number of subjects: 60
Study 15557857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreserved timolol
Number of subjects: 73
Study 15557857 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate gel-forming solution
Number of subjects: 73
Study 12790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (20 mg, twice daily for 6 weeks)
Number of subjects: 23
Study 12790983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 23
Study 9120495 — intervention group
Group type: EXPERIMENTAL
Intervention: Biexponential decay lesions (50 lesions)
Number of subjects: 40
Study 9120495 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoexponential decay lesions (70 lesions)
Number of subjects: 40
Study 9120495 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 40
Study 9120495 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with disability
Number of subjects: 40
Study 8292515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral megadose methylprednisolone (MDMP)
Number of subjects: 20
Study 8292515 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin G (IV IgG)
Number of subjects: 20
Study 2880161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg once daily
Number of subjects: 51
Study 2880161 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 51
Study 30452394 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagonal Active Stretching (DS)
Number of subjects: 24
Study 30452394 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 24
Study 30452394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DS and SS)
Number of subjects: 24
Study 30024811 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with cash incentives, supply chain support, and monthly clinical supervision.
Number of subjects: 0
Study 30024811 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention for diarrhea treatment.
Number of subjects: 0
Study 30024811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHW intervention).
Number of subjects: 0
Study 26867498 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer (NL) alone
Number of subjects: 48
Study 26867498 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer (NL) plus cosmetic nail varnish
Number of subjects: 48
Study 26867498 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Amorolfine 5% NL alone and NL plus cosmetic nail varnish)
Number of subjects: 48
Study 26867498 — intervention group
Group type: COMPARATOR
Intervention: Cosmetic nail varnish
Number of subjects: 48
Study 24549549 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 127
Study 24549549 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 127
Study 24549549 — intervention group
Group type: COMPARATOR
Intervention: Quality of life measures
Number of subjects: 127
Study 22545894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 40
Study 22545894 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (BA)
Number of subjects: 40
Study 19879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 x 2 g daily for 14 days)
Number of subjects: 40
Study 19879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (3 x 1 g daily for 14 days)
Number of subjects: 40
Study 17356989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention
Number of subjects: 613
Study 17356989 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 613
Study 16238119 — intervention group
Group type: EXPERIMENTAL
Intervention: Novo‐Helisen Depot allergy vaccines for 3 years
Number of subjects: 56
Study 16238119 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of treatment
Number of subjects: 56
Study 12235690 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic group
Number of subjects: 23
Study 10524722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy over a period of 8 weeks
Number of subjects: 0
Study 10524722 — intervention group
Group type: COMPARATOR
Intervention: No changes to treatment status (Control)
Number of subjects: 0
Study 10524722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0
Study 7788130 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 34
Study 7788130 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 34
Study 2092963 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 42
Study 2092963 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 2 mg
Number of subjects: 42
Study 655936 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 655936 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol + other adrenergic amines (norepinephrine, epinephrine)
Number of subjects: 0
Study 30318240 — intervention group
Group type: EXPERIMENTAL
Intervention: USG-guided SLN block bilaterally with 2.5 ml of 2% lignocaine along with GA (Group L)
Number of subjects: 40
Study 30318240 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) alone (Group C)
Number of subjects: 40
Study 27802910 — intervention group
Group type: EXPERIMENTAL
Intervention: Indianapolis Vocational Intervention Program (IVIP)
Number of subjects: 64
Study 27802910 — intervention group
Group type: COMPARATOR
Intervention: Support therapy group (SG)
Number of subjects: 64
Study 25996273 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diabetes risk assessments and point-of-care measurement of HbA(1c) during retinal ophthalmologic visits.
Number of subjects: 1756
Study 25996273 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1756
Study 22868407 — intervention group
Group type: EXPERIMENTAL
Intervention: PSNB in combination with an obturator nerve block (obturator group, n = 20)
Number of subjects: 40
Study 22868407 — intervention group
Group type: COMPARATOR
Intervention: PSNB alone (control group, n = 20)
Number of subjects: 40
Study 21271182 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic solution (Gatorade(®))
Number of subjects: 99
Study 21271182 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 99
Study 21271182 — intervention group
Group type: COMPARATOR
Intervention: Control (200 mL water)
Number of subjects: 99
Study 19478547 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5% and tropicamide 1% (group 0)
Number of subjects: 58
Study 19478547 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 10% and tropicamide 1% (group 1)
Number of subjects: 58
Study 16460486 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybum marianum (600 mg or 1200 mg/day)
Number of subjects: 24
Study 16460486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15321699 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 75
Study 15321699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C co-infusion
Number of subjects: 75
Study 15321699 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP serum levels correlation
Number of subjects: 75
Study 11571244 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐galactosidase A therapy
Number of subjects: 0
Study 11571244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9610942 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg with alcohol (0.75 g ethanol/kg b.wt.)
Number of subjects: 0
Study 9610942 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 15 mg with alcohol (0.75 g ethanol/kg b.wt.)
Number of subjects: 0
Study 9610942 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem with alcohol (0.75 g ethanol/kg b.wt.)
Number of subjects: 0
Study 9610942 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 7821190 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 injections per day with a pen injector
Number of subjects: 78
Study 2468877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 31
Study 2468877 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 31
Study 2468877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 31
Study 2468877 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 31
Study 2468877 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 31
Study 31809878 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 183
Study 31809878 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 183
Study 29651853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel‐S10
Number of subjects: 32
Study 29651853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 28464963 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 74
Study 28464963 — intervention group
Group type: EXPERIMENTAL
Intervention: CANTAB
Number of subjects: 74
Study 26700184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4‐methylenedioxymethamphetamine (MDMA)
Number of subjects: 0
Study 26700184 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (MPH)
Number of subjects: 0
Study 26700184 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA/MPH
Number of subjects: 0
Study 26700184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26700184 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA/MPH, MDMA, MPH
Number of subjects: 0
Study 26700184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature NK cells
Number of subjects: 0
Study 23138387 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 39
Study 23138387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation (CA)
Number of subjects: 39
Study 21153402 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF therapy
Number of subjects: 70
Study 21153402 — intervention group
Group type: COMPARATOR
Intervention: Immunoparalysis (TNFα response <200 pg/mL)
Number of subjects: 70
Study 19036670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (initial dose of 100 mg, followed by 50 mg intravenously every 12 hours for 5-14 days)
Number of subjects: 283
Study 19036670 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500/500 mg intravenously every 6 hours for 5-14 days)
Number of subjects: 283
Study 19036670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 283
Study 19036670 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 283
Study 16385401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 51
Study 14532998 — intervention group
Group type: EXPERIMENTAL
Intervention: One arterial infusion of cisplatin
Number of subjects: 40
Study 14532998 — intervention group
Group type: EXPERIMENTAL
Intervention: Two arterial infusions of cisplatin
Number of subjects: 40
Study 14532998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 40
Study 14532998 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 protein expression
Number of subjects: 40
Study 11070752 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (maximum dose 600 mg per day)
Number of subjects: 60
Study 11070752 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (maximum dose 150 mg per day)
Number of subjects: 60
Study 8968702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product (200 ml daily)
Number of subjects: 87
Study 8968702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 ml daily)
Number of subjects: 87
Study 1621746 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 390
Study 1621746 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500 mg three times daily)
Number of subjects: 390
Study 1621746 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times daily)
Number of subjects: 390
Study 6434883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thio-TEPA
Number of subjects: 46
Study 6434883 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 46
Study 30961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (ENCHANTED trial)
Number of subjects: 770
Study 30057103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive with polyurethane dressing
Number of subjects: 1807
Study 30057103 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing
Number of subjects: 1807
Study 30057103 — intervention group
Group type: EXPERIMENTAL
Intervention: Securement device with polyurethane dressing
Number of subjects: 1807
Study 30057103 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane dressing (control)
Number of subjects: 1807
Study 26847486 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 36
Study 26847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus resin composite restoration (CTG+RC)
Number of subjects: 36
Study 26847486 — intervention group
Group type: COMPARATOR
Intervention: CTG
Number of subjects: 36
Study 26847486 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG+RC
Number of subjects: 36
Study 24454970 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of AmBisome (7 times 3 mg/kg on days 1-5, 14, and 21)
Number of subjects: 124
Study 24454970 — intervention group
Group type: COMPARATOR
Intervention: Single dose of AmBisome 7.5 mg/kg
Number of subjects: 124
Study 24454970 — intervention group
Group type: COMPARATOR
Intervention: Single dose of AmBisome 10 mg/kg
Number of subjects: 124
Study 24454970 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of AmBisome
Number of subjects: 124
Study 21733953 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg)
Number of subjects: 30
Study 19781124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention activities focused on lifestyle modification to decrease dietary Na intake; Duration: 10 weeks; Supervised by a registered dietitian.
Number of subjects: 0
Study 19781124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-sample with urine volume of >or=1000 ml; Baseline to 12 months.
Number of subjects: 0
Study 18058622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (1000 IU per orally five days per week for 10 weeks)
Number of subjects: 44
Study 18058622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 44
Study 16219099 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of pre-hospital emergency pathway (training module and administration of the guideline)
Number of subjects: 750
Study 16219099 — intervention group
Group type: COMPARATOR
Intervention: Current practice (no intervention)
Number of subjects: 750
Study 17628384 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Number of subjects: 28
Study 17628384 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glyburide
Number of subjects: 28
Study 10794196 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program focusing on self-regulation skills and physical activity
Number of subjects: 570
Study 10794196 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570
Study 8797306 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR‐MWP system for detecting Helicobacter pylori DNA
Number of subjects: 0
Study 8797306 — intervention group
Group type: COMPARATOR
Intervention: Nested‐PCR system (commercial reference laboratory)
Number of subjects: 0
Study 1293975 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg)
Number of subjects: 6
Study 1293975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6147121 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol with glucagon
Number of subjects: 0
Study 6147121 — intervention group
Group type: COMPARATOR
Intervention: Propranolol with glucagon
Number of subjects: 0
Study 29252113 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) treatment with lymphatic correction plus muscle facilitation
Number of subjects: 26
Study 29252113 — intervention group
Group type: COMPARATOR
Intervention: Sham KT
Number of subjects: 26
Study 30248217 — intervention group
Group type: EXPERIMENTAL
Intervention: N9-GP 40 IU/kg once-weekly prophylaxis
Number of subjects: 115
Study 26867076 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 202
Study 26867076 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based exercise
Number of subjects: 202
Study 26867076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline therapy (50-200 mg daily)
Number of subjects: 202
Study 26867076 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 202
Study 24582532 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 23508
Study 24582532 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose statin (atorvastatin 10 mg, simvastatin 20 to 40 mg, or placebo)
Number of subjects: 23508
Study 24582532 — intervention group
Group type: COMPARATOR
Intervention: High-dose versus usual-dose statin or placebo
Number of subjects: 23508
Study 24582532 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 23508
Study 24582532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 23508
Study 24582532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist use
Number of subjects: 23508
Study 24582532 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous statin use
Number of subjects: 23508
Study 22414277 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (60 mg/day) with quetiapine (300-450 mg/day)
Number of subjects: 64
Study 22414277 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (60 mg/day) with placebo
Number of subjects: 64
Study 20456735 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose (100 microg)
Number of subjects: 8
Study 20456735 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic dose (60 mg)
Number of subjects: 8
Study 18515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweep
Number of subjects: 300
Study 18515514 — intervention group
Group type: COMPARATOR
Intervention: No sweep (control)
Number of subjects: 300
Study 18515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweep (with cervix > 1 cm dilated)
Number of subjects: 300
Study 18515514 — intervention group
Group type: COMPARATOR
Intervention: No sweep (with cervix > 1 cm dilated)
Number of subjects: 300
Study 15839185 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management by a clinical pharmacist
Number of subjects: 80
Study 15839185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 12430368 — intervention group
Group type: EXPERIMENTAL
Intervention: Promogran
Number of subjects: 73
Study 12430368 — intervention group
Group type: COMPARATOR
Intervention: Adaptic (Control)
Number of subjects: 73
Study 10512386 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling alone
Number of subjects: 20
Study 10512386 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with adjunctive antimicrobial therapy
Number of subjects: 20
Study 10512386 — intervention group
Group type: COMPARATOR
Intervention: Both groups received supportive periodontal therapy at 3, 6, 9, 12, 18, and 24 months
Number of subjects: 20
Study 7856987 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine resistance
Number of subjects: 187
Study 7856987 — intervention group
Group type: COMPARATOR
Intervention: Didanosine
Number of subjects: 187
Study 31194965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-containing antiretroviral regimens
Number of subjects: 15
Study 31194965 — intervention group
Group type: COMPARATOR
Intervention: Non-ritonavir-containing regimens or no antiretrovirals
Number of subjects: 15
Study 29352831 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish Food-Based Dietary Guidelines (FBDG) adherence indicated by Dietary Quality Index (DQI)
Number of subjects: 219